Status:
COMPLETED
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Lead Sponsor:
Pfizer
Conditions:
Melanoma
Skin Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to part...
Eligibility Criteria
Inclusion
- Histologically documented melanoma with metastases
- No more than 1 prior systemic therapy for metastatic disease (prior adjuvant therapy with interferon does not count as prior therapy for metastatic disease)
Exclusion
- History of hemoptysis (coughing up of blood)
- Brain metastases
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00094107
Start Date
December 1 2004
End Date
April 1 2008
Last Update
June 26 2012
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Orange, California, United States, 92868
2
Pfizer Investigational Site
Miami Beach, Florida, United States, 33140
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
4
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115